Uptake of Entresto (NVS) in the US has been slow following approval in July 2015. Part of that is due to the time it has taken to secure insurance coverage, but physicians have complained about other insurance barriers, as well, and there are also clinical factors that could play a role. This 6-question survey of 23 cardiologists asks about the most important clinical and reimbursement barriers for the drug. It also projects how changes in guidelines, prior-authorization, and copays could impact usage.